The value of a baseline bone scan in patients with newly diagnosed prostate cancer

Clinical Nuclear Medicine

Volumn 24, Issue 8, 1999, Pages 579-582

  Lin, Ke ^a   Szabo, Zsolt ^a   Chin, Bennett B ^a   Civelek, A Cahid ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Bone Scan; Gleason score; Prostate cancer; Prostate specific antigen; Tumor extent

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CANCER STAGING; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0032770076     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199908000-00007     Document Type: Article

References (20)

1. Haas GP, Sakr WA: Epidemiology of prostate cancer. CA 47:273, 1997.
2. Garnick MB: Prostate cancer: Screening, diagnosis and management. Ann Intern Med 118:804, 1993.
3. Whitemore WF Jr: National history and staging of prostate cancer. Urol Clin North Am 11:209, 1984.
4. Murphy GP, Natarajan N, Pontes JE: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 127:928, 1982.
5. Schaffer DL, Pendergrass HP: Comparison of enzyme, clinical, radiographiC, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 121:431, 1976.
6. McCarthy P, Pollack HM: Imaging of patients with stage D prostate carcinoma. Urol Clin North Am 18:35, 1991.
7. Lee CT, Oesterling JE: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24:389, 1997.
8. Small EJ: Prostate cancer. Current Opinion in Oncology 9:277, 1997.
9. D'Amoco AV, Desjardin A, Chung A, et al: Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer 82:1887, 1998.
10. Small EJ: Updates on the diagnosis and treatment of prostate cancer Current Opinion in Oncology 10:244, 1998.
11. Koch MO, Miller DA, Butler R, et al: Are we selecting the right patients for treatment of localized prostate cancer? Results of an actuarial analysis. Urology 51:197, 1998.
12. Wolf JM Bares R, Jung RK, et al: Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 156:169, 1996.
13. Huncharek M, Muscat J: Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Cancer Invest 13:31, 1995.
14. Oesterling JE, Martin SK, Bergstrahl EJ, et al: The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269:57, 1993.
15. Chybowski FM, Keller JJ, Bergstralh EJ, et al: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 145:313, 1991.
16. Jacobson AF, Hammersmith SM: Value of the baseline bone scan in patients with newly diagnosed prostate cancer and low prostate specific antigen level [Abstract], J Nucl Med 38(S):301P, 1997.
17. Haden HT, Katz PG, Konerding KF: Detection of obstructive uropathy by bone scintigraphy. J Nucl Med 29:1781, 1988.
18. Balachandran S, Angtuaco TL, Shah HR, et al: Incidental hydronephrosis on bone scintigraphy: Sonographic verification. J Urol 134:649, 1985.
19. Pilbrow WJ: The urinary tract image obtained during 99mTc bone scanning. Clin Radiol 30:71, 1979.
20. Flores LG II, Nagamachi S, Jinnouchi S, et al: Relationship between extraosseous accumulation in bone scintigraphy with 99mTc-HMDP and histopathology. Nucl Med Commun 19:347, 1998.